TPST: Tempest Therapeutics Inc Kompaniya qiymatining sof foydaga nisbati
Tempest Therapeutics molekulyar kombinatsiyalarni sinovdan o'tkazish uchun sog'liqni saqlash gigantlari bilan ittifoqlar tuzgan holda onkologik davolash vositalarini ishlab chiqmoqda. -0.10 indikatori aks etgan ushbu narxlar grafigi aktivning dinamikasini vizuallashtiradi va bozor baholovini tasdiqlovchi vosita bo'lib xizmat qiladi. Biznes kichik molekulali patentlarni monetizatsiyalashga tayanadi, bunda litsenziyalash shartnomalari va innovatsion ishlanmalarning kelgusidagi tijoratlashtirilishidan foyda ko'ruvchi hisoblanadi.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_TPST_-_Tempest-Therapeutics_-_PE-Multiple "TPST: tempesttx.com Narx-foyda koeffitsiyenti 04.07.2022 - 11.11.2026 | 👁️GURU.Markets👁️")
Tempest Tx (TPST) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Barcha qarzlarning o‘z mablag‘lariga nisbati Tempest Therapeutics|TPST - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Tempest Therapeutics Corp|TPST - Kompaniyaning umumiy qarzi|Qarzning balans kapitaliga nisbati Tempest Therapeutics, Inc.|TPST - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Tempest Therapeutics|Tezkor likvidlik ko‘rsatkichi tempesttx.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
TPST - Kompaniyaning sof foydasi|Forvard foyda Tempest Therapeutics|TPST - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Tempest Therapeutics Inc|TPST - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Tempest Therapeutics, Inc.|TPST - Eskirish chegirilmasdan oldingi operatsion foyda|So'nggi to'rtta chorak uchun bir aksiya uchun foyda Tempest Therapeutics|TPST - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi tempesttx.com|TPST - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi Tempest Therapeutics
Kompaniyaning umumiy tahlili:tempesttx.com, TPST
P/E koeffitsiyenti bozor kapitalizatsiyasining yillik sof foydaga nisbatini o'lchaydi, bu esa investorga aktiv uchun haddan tashqari to'lov darajasini baholash yoki foyda qisqarishi davrida adolatli qiymat chegirmasini aniqlash imkonini beradi. Tempest Therapeutics (TPST) kompaniyasining P/E trayektoriyasini tahlil qilishda, ushbu biotexnologiya kompaniyasi uchun foyda tashqi CDMO pudratchilarining ekologik qoidalarga rioya qilishiga kritik darajada bog'liqligini va bu biznesning baholanishiga bevosita ta'sir qilishini hisobga olish muhimdir.
Muhim raqobatchilar
ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (Ascentage)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|BCAX - P/E multiplikatori|Personalis (PSNL) - Narxning foydaga nisbati|Erasca Inc - Kompaniya qiymatining sof foydaga nisbati|DCTH (Delcath) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Y-mAbs Corp YMAB|Narx-foyda koeffitsiyenti AURA (Aura Biosciences, Inc.)|Bozor narxining sof foydaga nisbati CADL|P/E multiplikatori ARAY (Accuray)|SELLAS Life Sciences Group, Inc. (SLS) - Kapitalizatsiyaning foydaga nisbati|ACTU - Narxning foydaga nisbati|Citius Oncology Inc (CTOR) - Narx-foyda koeffitsiyenti|tuhurabio.com (HURA) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati TARA (protaratx.com)|FATE (Fate Therapeutics) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aadi Bio WHWK|Narxning foydaga nisbati TScan Therapeutics (TCRX)|Biznesning o‘zini qoplash muddati championsoncology.com|XBiotech - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati CVM (CEL-SCI Corp.)|OSTX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati RADX (radiopharmtheranostics.com)|ARTV (artivabio.com) - Narx-foyda koeffitsiyenti|ANL: Bozor narxining sof foydaga nisbati|VERU (Veru Inc.) - P/E multiplikatori|XLO: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori RENB|MURA - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Kairos Pharma KAPA|Kompaniya qiymatining sof foydaga nisbati OKUR|CytoMed - P/E multiplikatori|CRIS - P/E multiplikatori|apollomicsinc.com (APLM) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati THAR (Tharimmune Inc)|ADVB (Advanced Biomed Inc.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Genprex Inc GNPX|Narx-foyda koeffitsiyenti CLDI (Calidi Biotherapeutics)|P/E multiplikatori sunshinebiopharma.com (SBFM)|Xenetic Biosciences, Inc. - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati SLRX (Salarius Pharmaceuticals Inc)|Purple Biotech Corp - P/E multiplikatori|Biznesning o‘zini qoplash muddati American Oncology Network AONC|BGNE: P/E multiplikatori|Narx-foyda koeffitsiyenti checkpointtx.com|Narxning foydaga nisbati Elevation Oncology|iCAD Corp (ICAD) - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti IKNA (Ikena Oncology, Inc.)|Bozor narxining sof foydaga nisbati NTBL|Narxning foydaga nisbati Viracta Therapeutics, Inc. VIRX|MOR (morphosys.com) - Kapitalizatsiyaning sof foydaga nisbati|NAYA - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Ascentage Pharma Group International AAPGV
